|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2002
Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study
1 Lung Pathology Unit, Dept of Gene Therapy, National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London, UK. 2 Asthma Research Centre, University of Uppsala, Uppsala, Sweden. 3 University Hospital, Dept of Pulmonary Medicine, Gentofte, Denmark. 4 University Hospital, Dept of Pulmonary Medicine, Aarhus, Denmark
CORRESPONDENCE: P.K. Jeffery, Lung Pathology, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK. Fax: 44 20 73518435. E-mail: p.jeffery@ic.ac.uk
Keywords: asthma, biopsy, inflammation, neutrophil, salmeterol xinafoate
Received: April 26, 2002
Accepted July 12, 2002
This study was supported by GlaxoSmithKline Research & Development Ltd, London, UK.
Although the anti-inflammatory effects of inhaled corticosteroids in the treatment of asthma are established, the effects of long-acting ß2-adrenergic receptor agonists on inflammation are the subject of debate. The aim of the present study was to determine the effect of salmeterol on the numbers of inflammatory cells in biopsy samples of distinct immunophenotype and those expressing the genes for interleukin-4 and -5, regulatory cytokines particularly relevant to asthma.
Twenty patients (aged 18–55 yrs) with mild stable asthma were randomised in a three-way crossover study to 6 weeks of treatment with: 1) salmeterol (50 µg b.d.; SM50); 2) fluticasone propionate (250 µg b.d.; FP250), or 3) placebo.
Compared with placebo, SM50 significantly reduced the numbers of neutrophils in bronchial biopsy samples and the concentrations of myeloperoxidase and soluble E-selectin in serum, each of which reflect neutrophil involvement. Compared with FP250, SM50 reduced neutrophil number and human neutrophil lipocalin level in bronchial lavage fluid and intercellular adhesion molecule-1 level in bronchoalveolar lavage fluid. Compared with placebo, FP250 significantly reduced the numbers of (CD3+) T-lymphocytes, (CD4+) T-helper cells, (CD45RO+) activated T-helper cells and eosinophils in the biopsy samples; it also reduced the percentage of eosinophils and soluble intercellular adhesion molecule-1 in serum. The percentage of symptom-free days and nights and airways hyperresponsiveness improved significantly after SM50 compared to both placebo and FP250.
In conclusion, a novel antineutrophilic effect of the inhaled long-acting ß2-adrenergic receptor agonist, salmeterol, in mild asthma is reported.
This article has been cited by other articles:
|
|
 |
|
  A. M. Wood and R. A. Stockley Editorial: Unifying the genetics, co-morbidities and management of COPD Therapeutic Advances in Respiratory Disease, June 1, 2008; 2(3): 113 - 117. [PDF]
|
|
|
|
 |
|
 J. Bourbeau, P. Christodoulopoulos, F. Maltais, Y. Yamauchi, R. Olivenstein, and Q. Hamid Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial Thorax, November 1, 2007; 62(11): 938 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes Scientific rationale for using a single inhaler for asthma control Eur. Respir. J., March 1, 2007; 29(3): 587 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. Barnes, Y.-S. Qiu, I. D. Pavord, D. Parker, P. A. Davis, J. Zhu, M. Johnson, N. C. Thomson, P. K. Jeffery, and on behalf of the SCO30005 Study Group Antiinflammatory Effects of Salmeterol/Fluticasone Propionate in Chronic Obstructive Lung Disease Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 736 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cheung, H. C. J. van Klink, R. Aalbers, and for the OZON study group Improved lung function and symptom control with formoterol on demand in asthma. Eur. Respir. J., March 1, 2006; 27(3): 504 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Proskocil and A. D. Fryer {beta}2-Agonist and Anticholinergic Drugs in the Treatment of Lung Disease Proceedings of the ATS, November 1, 2005; 2(4): 305 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Maneechotesuwan, S. Essilfie-Quaye, S. Meah, C. Kelly, S. A. Kharitonov, I. M. Adcock, and P. J. Barnes Formoterol Attenuates Neutrophilic Airway Inflammation in Asthma Chest, October 1, 2005; 128(4): 1936 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Peek, D. F. Richards, A. Faith, P. Lavender, T. H. Lee, C. J. Corrigan, and C. M. Hawrylowicz Interleukin-10-Secreting "Regulatory" T Cells Induced by Glucocorticoids and {beta}2-Agonists Am. J. Respir. Cell Mol. Biol., July 1, 2005; 33(1): 105 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barnes and R. A. Stockley COPD: current therapeutic interventions and future approaches Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Linden, M. Laan, and G. P. Anderson Neutrophils, interleukin-17A and lung disease Eur. Respir. J., January 1, 2005; 25(1): 159 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Chanez, A. Bourdin, I. Vachier, P. Godard, J. Bousquet, and A. M. Vignola Effects of Inhaled Corticosteroids on Pathology in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 184 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gabrijelcic, A. Casas, R.A. Rabinovich, J. Roca, J.A. Barbera, K.F. Chung, and R. Rodriguez-Roisin Formoterol protects against platelet-activating factor-induced effects in asthma Eur. Respir. J., January 1, 2004; 23(1): 71 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jeffery, S. Holgate, and S. Wenzel Methods for the Assessment of Endobronchial Biopsies in Clinical Research: Application to Studies of Pathogenesis and the Effects of Treatment Am. J. Respir. Crit. Care Med., September 15, 2003; 168(6): S1 - 17. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |